The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Pasithea Therapeutics Corp shares valued at $100,000 were purchased by STEINMAN LAWRENCE on Nov 28 ’25. At $0.75 per share, STEINMAN LAWRENCE acquired 133,333 shares. The insider’s holdings grew to 199,691 shares worth approximately $0.26 million following the completion of this transaction.
Also, Marques Tiago purchased 33,333 shares, netting a total of over 25,000 in proceeds. Following the buying of shares at $0.75 each, the insider now holds 73,334 shares.
Before that, Dumesnil Simon had added 33,333 shares to its account. In a trade valued at $25,000, the Director bought Pasithea Therapeutics Corp shares for $0.75 each. Upon closing the transaction, the insider’s holdings increased to 33,333 shares, worth approximately $46224.57.
Analyzing KTTA Stock Performance
On last trading session, Pasithea Therapeutics Corp [NASDAQ: KTTA] rose 12.17% to $1.29. The stock’s lowest price that day was $1.14, but it reached a high of $1.3 in the same session. During the last five days, there has been a surge of approximately 11.21%. Over the course of the year, Pasithea Therapeutics Corp shares have dropped approximately -52.75%. Shares of the company reached a 52-week high of $3.8500 on 02/05/25 and a 52-week low of $0.2810 on 11/21/25.
Support And Resistance Levels for Pasithea Therapeutics Corp (KTTA)
According to the 24-hour chart, there is a support level at 1.1867, which, if violated, would cause prices to drop to 1.0833. In the upper region, resistance lies at 1.3467. The next price resistance is at 1.4033. RSI (Relative Strength Index) is 65.45 on the 14-day chart, showing neutral technical sentiment.
Is Pasithea Therapeutics Corp subject to short interest?
Stocks of Pasithea Therapeutics Corp saw a sharp rise in short interest on 2025-12-15 jumping by 0.43 million shares to 0.45 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 23343.0 shares. A jump of 94.84% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.02 of the overall float, the days-to-cover ratio (short ratio) jumped to 0.02.
Which companies own the most shares of Pasithea Therapeutics Corp (KTTA)?
In terms of Pasithea Therapeutics Corp share price expectations, FactSet research, analysts set an average price target of 3 in the next 12 months, up nearly 160.87% from the previous closing price of $1.15. Analysts anticipate Pasithea Therapeutics Corp stock to reach 3 by 2026, with the lowest price target being 3.
